Comparison of Pemetrexed and Docetaxel as Salvage Chemotherapy for the Treatment of Non-Small-Cell Lung Cancer After the Failure of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

    January 2014 in “ Journal of international medical research ”
    Dong Li, Zhaofeng Han, Zihui Feng, Zhiyang Jia
    TLDR Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.
    In a randomized Phase 2 trial comparing pemetrexed and docetaxel as salvage chemotherapy for nonsmall-cell lung cancer (NSCLC) patients after failure of EGFR-TKI therapy, no significant differences were found in disease control rate, response rate, median survival, and 1-year survival between the two treatments. However, adverse effects such as nausea, myelosuppression, renal damage, and hair loss were significantly higher in the docetaxel group. Pemetrexed was found to be effective and well-tolerated, suggesting it may be a suitable therapeutic option for these patients.
    Discuss this study in the Community →